[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fIXlWfTu6mjSBlvk-uAFw-cfDHW9nJlwbwesTLcRvpYE":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":65,"rows":72},"Foundation University Islamabad",[4],218,false,107,0,10076,8,209,[14,17,20,23,26,28,30,33],{"name":15,"count":16},"Low Back Pain",16,{"name":18,"count":19},"Balance",12,{"name":21,"count":22},"Neck Pain",11,{"name":24,"count":25},"Stroke",6,{"name":27,"count":25},"Knee Osteoarthritis",{"name":29,"count":25},"Adhesive Capsulitis",{"name":31,"count":32},"Low Back Pain, Mechanical",5,{"name":34,"count":32},"Cervicogenic Headache",[36,41,46,51,56,60],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT06609941","Additive Effects of Alternative Nostril Breathing with Pharmacological Management on Dyspnea and Control Pause in Patients with Bronchial Asthma","2025-01-01","Pharmacological therapy",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT07388407","Pharmacogenetics of Leflunomide in the Management of Rheumatoid Arthritis","2026-06-30","Study for the correlation of SNPs with efficacy and toxicity of Leflunomide in RA patients",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT07519174","A Randomized Controlled Trial Comparing the Effectiveness and Safety of Topical Tacrolimus 0.03% Versus Crisaborole 2% in Patients With Mild to Moderate Atopic Dermatitis Over 8 Weeks","2026-11-01","Tacrolimus",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT07485777","Comparative Evaluation of Topical 30% Metformin and Kligman's Regimen in Women With Melasma","2026-12-01","Topical 30% metformin cream",{"nctId":57,"briefTitle":58,"date":54,"intervention":59},"NCT07495748","Comparative Evaluation of Topical Metformin and Topical Tranexamic Acid in Melasma","topical 3% tranexamic acid solution",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT07180394","Botulinum Toxin for Strabismus Treatment","2030-08-30","Botox injection into extraocular muscles",[66,67,68,69,70,71],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[73,105,129,147,165,183,205,228,250,277,295,321,339,365],{"intervention":55,"totalTrials":74,"cells":75},2,{"EARLY_PHASE1":76,"PHASE1":78,"PHASE2":80,"PHASE3":82,"PHASE4":84,"NA":86},{"trials":77,"activeCount":9},[],{"trials":79,"activeCount":9},[],{"trials":81,"activeCount":9},[],{"trials":83,"activeCount":9},[],{"trials":85,"activeCount":9},[],{"trials":87,"activeCount":74,"soonestReadout":54},[88,99],{"nctId":52,"briefTitle":53,"status":89,"phases":90,"primaryCompletion":54,"completion":91,"start":92,"enrollment":93,"conditions":94,"interventions":97},"NOT_YET_RECRUITING",[71],"2027-06-01","2026-07-01",82,[95,96],"Melasma (Facial Melasma)","Melasma",[55,98],"Kligman's Regimen",{"nctId":57,"briefTitle":58,"status":89,"phases":100,"primaryCompletion":54,"completion":101,"start":92,"enrollment":102,"conditions":103,"interventions":104},[71],"2027-07-01",70,[96],[59,55],{"intervention":50,"totalTrials":106,"cells":107},1,{"EARLY_PHASE1":108,"PHASE1":110,"PHASE2":112,"PHASE3":114,"PHASE4":116,"NA":118},{"trials":109,"activeCount":9},[],{"trials":111,"activeCount":9},[],{"trials":113,"activeCount":9},[],{"trials":115,"activeCount":9},[],{"trials":117,"activeCount":9},[],{"trials":119,"activeCount":106,"soonestReadout":49},[120],{"nctId":47,"briefTitle":48,"status":89,"phases":121,"primaryCompletion":49,"completion":122,"start":123,"enrollment":124,"conditions":125,"interventions":127},[71],"2027-01-01","2026-06-01",72,[126],"Atopic Dermatitis",[50,128],"Crisaborole 2% Top Oint",{"intervention":128,"totalTrials":106,"cells":130},{"EARLY_PHASE1":131,"PHASE1":133,"PHASE2":135,"PHASE3":137,"PHASE4":139,"NA":141},{"trials":132,"activeCount":9},[],{"trials":134,"activeCount":9},[],{"trials":136,"activeCount":9},[],{"trials":138,"activeCount":9},[],{"trials":140,"activeCount":9},[],{"trials":142,"activeCount":106,"soonestReadout":49},[143],{"nctId":47,"briefTitle":48,"status":89,"phases":144,"primaryCompletion":49,"completion":122,"start":123,"enrollment":124,"conditions":145,"interventions":146},[71],[126],[50,128],{"intervention":98,"totalTrials":106,"cells":148},{"EARLY_PHASE1":149,"PHASE1":151,"PHASE2":153,"PHASE3":155,"PHASE4":157,"NA":159},{"trials":150,"activeCount":9},[],{"trials":152,"activeCount":9},[],{"trials":154,"activeCount":9},[],{"trials":156,"activeCount":9},[],{"trials":158,"activeCount":9},[],{"trials":160,"activeCount":106,"soonestReadout":54},[161],{"nctId":52,"briefTitle":53,"status":89,"phases":162,"primaryCompletion":54,"completion":91,"start":92,"enrollment":93,"conditions":163,"interventions":164},[71],[95,96],[55,98],{"intervention":59,"totalTrials":106,"cells":166},{"EARLY_PHASE1":167,"PHASE1":169,"PHASE2":171,"PHASE3":173,"PHASE4":175,"NA":177},{"trials":168,"activeCount":9},[],{"trials":170,"activeCount":9},[],{"trials":172,"activeCount":9},[],{"trials":174,"activeCount":9},[],{"trials":176,"activeCount":9},[],{"trials":178,"activeCount":106,"soonestReadout":54},[179],{"nctId":57,"briefTitle":58,"status":89,"phases":180,"primaryCompletion":54,"completion":101,"start":92,"enrollment":102,"conditions":181,"interventions":182},[71],[96],[59,55],{"intervention":64,"totalTrials":106,"cells":184},{"EARLY_PHASE1":185,"PHASE1":187,"PHASE2":189,"PHASE3":191,"PHASE4":193,"NA":195},{"trials":186,"activeCount":9},[],{"trials":188,"activeCount":9},[],{"trials":190,"activeCount":9},[],{"trials":192,"activeCount":9},[],{"trials":194,"activeCount":9},[],{"trials":196,"activeCount":106,"soonestReadout":63},[197],{"nctId":61,"briefTitle":62,"status":89,"phases":198,"primaryCompletion":63,"completion":63,"start":199,"enrollment":200,"conditions":201,"interventions":204},[71],"2025-09-30",127,[202,203],"Strabismic Deviation","Strabismus",[64],{"intervention":40,"totalTrials":106,"cells":206},{"EARLY_PHASE1":207,"PHASE1":209,"PHASE2":211,"PHASE3":213,"PHASE4":215,"NA":217},{"trials":208,"activeCount":9},[],{"trials":210,"activeCount":9},[],{"trials":212,"activeCount":9},[],{"trials":214,"activeCount":9},[],{"trials":216,"activeCount":9},[],{"trials":218,"activeCount":106,"soonestReadout":39},[219],{"nctId":37,"briefTitle":38,"status":220,"phases":221,"primaryCompletion":39,"completion":222,"start":223,"enrollment":224,"conditions":225,"interventions":227},"RECRUITING",[71],"2025-02-01","2024-06-18",32,[226],"Bronchial Asthma",[40],{"intervention":45,"totalTrials":106,"cells":229},{"EARLY_PHASE1":230,"PHASE1":232,"PHASE2":234,"PHASE3":236,"PHASE4":238,"NA":240},{"trials":231,"activeCount":9},[],{"trials":233,"activeCount":9},[],{"trials":235,"activeCount":9},[],{"trials":237,"activeCount":9},[],{"trials":239,"activeCount":9},[],{"trials":241,"activeCount":106,"soonestReadout":44},[242],{"nctId":42,"briefTitle":43,"status":220,"phases":243,"primaryCompletion":44,"completion":244,"start":245,"enrollment":246,"conditions":247,"interventions":249},[],"2026-09-30","2024-09-01",110,[248],"Rhematoid Arthritis",[45],{"intervention":251,"totalTrials":106,"cells":252},"Coumadin",{"EARLY_PHASE1":253,"PHASE1":255,"PHASE2":257,"PHASE3":259,"PHASE4":261,"NA":263},{"trials":254,"activeCount":9},[],{"trials":256,"activeCount":9},[],{"trials":258,"activeCount":9},[],{"trials":260,"activeCount":9},[],{"trials":262,"activeCount":9},[],{"trials":264,"activeCount":9},[265],{"nctId":266,"briefTitle":267,"status":268,"phases":269,"primaryCompletion":270,"completion":270,"start":271,"enrollment":272,"conditions":273,"interventions":275},"NCT03191305","Comparison of the Efficacy of Rivroxaban to Coumadin( Warfarin ) in Cerebral Venous Thrombosis","UNKNOWN",[71],"2018-09","2017-08",50,[274],"Cerebral Venous Thrombosis",[251,276],"Rivoroxaban",{"intervention":276,"totalTrials":106,"cells":278},{"EARLY_PHASE1":279,"PHASE1":281,"PHASE2":283,"PHASE3":285,"PHASE4":287,"NA":289},{"trials":280,"activeCount":9},[],{"trials":282,"activeCount":9},[],{"trials":284,"activeCount":9},[],{"trials":286,"activeCount":9},[],{"trials":288,"activeCount":9},[],{"trials":290,"activeCount":9},[291],{"nctId":266,"briefTitle":267,"status":268,"phases":292,"primaryCompletion":270,"completion":270,"start":271,"enrollment":272,"conditions":293,"interventions":294},[71],[274],[251,276],{"intervention":296,"totalTrials":106,"cells":297},"Nanohybrid Compisite Group",{"EARLY_PHASE1":298,"PHASE1":300,"PHASE2":302,"PHASE3":304,"PHASE4":306,"NA":308},{"trials":299,"activeCount":9},[],{"trials":301,"activeCount":9},[],{"trials":303,"activeCount":9},[],{"trials":305,"activeCount":9},[],{"trials":307,"activeCount":9},[],{"trials":309,"activeCount":9},[310],{"nctId":311,"briefTitle":312,"status":268,"phases":313,"primaryCompletion":314,"completion":314,"start":315,"enrollment":316,"conditions":317,"interventions":319},"NCT05644860","Nano Composites and Light Cure Composites - A Comparative Assessment of Bond Failure Rates",[71],"2023-06","2022-09-01",40,[318],"Nanotechnology, Dental Materials, Composites",[296,320],"Conventional Composite Group",{"intervention":320,"totalTrials":106,"cells":322},{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":329,"PHASE4":331,"NA":333},{"trials":324,"activeCount":9},[],{"trials":326,"activeCount":9},[],{"trials":328,"activeCount":9},[],{"trials":330,"activeCount":9},[],{"trials":332,"activeCount":9},[],{"trials":334,"activeCount":9},[335],{"nctId":311,"briefTitle":312,"status":268,"phases":336,"primaryCompletion":314,"completion":314,"start":315,"enrollment":316,"conditions":337,"interventions":338},[71],[318],[296,320],{"intervention":340,"totalTrials":106,"cells":341},"N-Acetylcysteine",{"EARLY_PHASE1":342,"PHASE1":344,"PHASE2":346,"PHASE3":348,"PHASE4":350,"NA":352},{"trials":343,"activeCount":9},[],{"trials":345,"activeCount":9},[],{"trials":347,"activeCount":9},[],{"trials":349,"activeCount":9},[],{"trials":351,"activeCount":9},[],{"trials":353,"activeCount":9},[354],{"nctId":355,"briefTitle":356,"status":268,"phases":357,"primaryCompletion":358,"completion":359,"start":360,"enrollment":102,"conditions":361,"interventions":363},"NCT06019520","Role of N-Acetylcysteine for Prevention of Cisplatin-induced Nephrotoxicity",[71],"2024-02-09","2024-03-09","2023-08-09",[362],"Drug Toxicity",[340,364],"Chemotherapy",{"intervention":364,"totalTrials":106,"cells":366},{"EARLY_PHASE1":367,"PHASE1":369,"PHASE2":371,"PHASE3":373,"PHASE4":375,"NA":377},{"trials":368,"activeCount":9},[],{"trials":370,"activeCount":9},[],{"trials":372,"activeCount":9},[],{"trials":374,"activeCount":9},[],{"trials":376,"activeCount":9},[],{"trials":378,"activeCount":9},[379],{"nctId":355,"briefTitle":356,"status":268,"phases":380,"primaryCompletion":358,"completion":359,"start":360,"enrollment":102,"conditions":381,"interventions":382},[71],[362],[340,364]]